EGFR and non-small cell lung carcinoma: In this study, we used a nontargeted metabolomics approach based on liquid chromatography-mass spectrometry to analyze the metabolic response of NSCLC patients to EGFR-TKIs or PD-1/PD-L1 inhibitors in an attempt to provide new clues to identifying the antitumor mechanism of these two treatments from the perspective of metabolism.